Wiley Matthew T. 4
4 · BioXcel Therapeutics, Inc. · Filed Jun 18, 2024
Insider Transaction Report
Form 4
Wiley Matthew T.
Other
Transactions
- Exercise/Conversion
Common Stock
2024-06-15+750→ 3,742 total - Sale
Common Stock
2024-06-17$1.26/sh−244$308→ 3,498 total - Exercise/Conversion
Restricted Stock Units
2024-06-15+750→ 8,250 total→ Common Stock (750 underlying)
Footnotes (3)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.
- [F3]On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.